For patients with unresectable hepatocellular carcinoma, the combination of atezolizumab and bevacizumab is associated with longer time to deterioration of patient-reported quality of life.
In China, researchers investigate the sustained virologic response and safety profile of coblopasvir plus sofosbuvir taken once daily for 12 weeks among patients with HCV genotypes 1, 2, 3, or 6 infections, including individuals with compensated cirrhosis.
The Public Health England Hepatitis C Virus Resistance Group recommended testing resistance for treatment of the hepatitis C virus by using a genotypic testing method of either the Sanger sequencing or next-generation sequencing methods.
Intolerance to treatment with direct acting antiviral treatment was found to be associated with older age and advanced liver disease in patients with hepatocellular carcinoma.
As emergency departments (EDs) are critical settings for hepatitis C care in the United States, investigators evaluated trends and characteristics of hepatitis C-associated ED visits from 2006 to 2014.
In a small patient cohort, researchers found that heart transplantation from donors who were hepatitis C virus-positive to recipients without the virus were successful.
The prevalence of hepatitis C virus in the US population born after 1985 and Mexican Americans is suggested by researchers to be due to the opioid epidemic.
Using data from an Egyptian cohort, investigators sought to determine the safety and efficacy of adding epigallocatechin gallate to sofosbuvir plus daclatasvir with or without ribavirin to treat patients with chronic hepatitis C virus.
Researchers hypothesized that because prior studies have demonstrated that common drugs can affect the microbiome, these medications could also impact IO efficacy in HCC.
Previous genomic profiling studies have identified potentially targetable alterations in IDH1 and FGFR2 in primary tumor specimens of some patients with IHCC.
In Wisconsin, researchers found data that showed people who inject drugs are susceptible to hepatitis A virus infection, and those aged over 35 are susceptible to hepatitis B infection.
In a clinical guideline from the American College of Gastroenterology, recommendations are presented for management of disorders of the hepatic and mesenteric circulation.
Nonalcoholic steatohepatitis (NASH) is expected to pose a significant clinical and economic burden during the next 20 years for U.S. patients with type 2 diabetes mellitus.
The Food and Drug Administration (FDA) has granted Orphan Drug designation to SFA001 (SFA Therapeutics) for the treatment of hepatocellular carcinoma (HCC).
The study researchers concluded that different DAA therapies may be safely used with high SVR12 rates in patients with HCV and GFR less than 30 ml/min, except for ribavirin due to poor tolerability.
